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Abstract and Keywords
There is a growing recognition of the impact of environmental toxins on the epigenetic
regulation of gene expression, including the genes that play a critical role in neural development,
neural function and neurodegeneration. We have shown previously that exposure to the heavy
metal lead (Pb) in early life results in a latent over-expression of AD-related proteins in rodents
and primates. The present study provides evidence that early postnatal exposure to Pb also alters
the expression of select miRNA. Mice were exposed to 0.2% Pb acetate from Postnatal Day 1
(PND 1, first 24 hours after birth) to PND 20 via their mother’s milk, brain tissue was harvested
at PND 20, 180, or 700 and miRNA were isolated and quantified by qPCR.

This exposure

produced a transient increase (relative to control) in the expression of miR-106b (binds to AβPP
mRNA), miR-29b (targets the mRNA for the transcription factor SP1) and two miRNAs (miR29b and miR-132) that have the ability to inhibit translation of proteins involved in promoter
methylation. The expression of miR-106b decreased over time in the Pb-exposed animals and
was significantly less than the levels exhibited by the control animals at PND700. The level of
miR-124, which binds to SP1 mRNA, was also reduced (relative to controls) at PND700.

In

summary, we show that exposure to the heavy metal Pb in early life has a significant impact on
the short- and long-term expression of miRNA that target epigenetic mediators and neurotoxic
proteins.

Key words: neurodegeneration; miRNA; lead; amyloid-β precursor protein; tau
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Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disease and the major
cause of dementia. A very small proportion (less than 5%) of individuals with AD develops the
disease before age 65, and is considered to have Early Onset Alzheimer’s Disease. The
overwhelming majority of AD cases are sporadic, or late onset AD (LOAD). To date, no
mutation, other than a risk associated with carrying certain susceptibility alleles (currently
numbering approximately 24), has been linked to LOAD [1-5]. The failure to identify a clear
genetic etiology for LOAD suggests the likelihood that environmental and/or epigenetic factors
play an important role in initiating and influencing the cascade of events that leads to this form
of AD [6].
There is a growing recognition of the impact of environmental factors such as heavy
metals, diet, pesticides and stress on the epigenetic regulation of gene expression, including the
genes that play a critical role in neural development, neural function and neurodegeneration [7,
8]. One toxicant that has generated particular concern is the heavy metal lead (Pb), and our
laboratory was in fact the first to provide evidence of a potential link between Pb and AD when it
demonstrated that exposure to Pb in early life resulted in latent over-expression of AD-related
proteins in rodents [9]. We found subsequently that developmental exposure to Pb produced a
transient increase in the binding of the transcription factor specificity protein 1 (SP1) to DNA,
together with a brief increase in the expression of the mRNA for amyloid-β precursor protein
(AβPP) and microtubule-associated protein tau (MAPT) [9-12]. This very transient increase was
followed by a delayed increase in SP1 binding together with a delayed overexpression of AβPP
mRNA, AβPP, amyloid-β (Aβ), Mapt mRNA and hyperphosphorylated tau in later life [9, 12,
13]. Importantly, these changes do not occur when animals are exposed to Pb in old age. The

3	
  	
  

Journal	
  of	
  Alzheimer’s	
  Disease,	
  Manuscript	
  15-‐1018R1	
  Accepted	
  01/11/16	
  

results we obtained using our rodent model of environmental Pb exposure have been verified and
expanded using tissue obtained from primates that were exposed to Pb during infancy. Tissue
obtained from the cerebral cortex of adult (23 years) monkeys exposed to Pb between PND 0400 exhibited pathologic neurodegeneration, an overexpression of SP1 mRNA, SP1, AβPP, Aβ,
MAPT mRNA and tau and a decrease in the expression of the methylation-related proteins DNA
(Cytosine-5-)-Methyltransferase (DNMT)1, DMNT3a and Methyl CpG Binding Protein 2
(MECP2) [14-16].
Our data regarding Pb-induced changes in SP1, DNMT1, DMNT3a and MeCP2 provide
support for the hypothesis that the delayed overexpression of AD-related proteins involves
changes to the epigenome. The challenge, therefore, is to identify a mechanism that can explain
the delayed emergence of epigenetic modifications that are “triggered” by an environmental
stimulus in early life. We suggest that the cancer literature offers some potentially important
insights. Work conducted by a number of laboratories has revealed an intriguing interaction
between transcription factors, DNMTs and microRNA (miRNA) during oncogenesis [17-22].
The interactions between SP1, the DNMTs and miRNA in oncogenesis provide a framework for
developing and testing postulates regarding the roles that epigenetic mediators and transcription
factors play in the development of LOAD. Our global hypothesis is that early-life exposure to
Pb is a toxic trigger that initiates a cascade of epigenetic changes, beginning with the transient
activation of the transcription factor SP1 and its brief activation of select subsets of miRNA. We
propose that subsequent accumulating stochastic changes alter miRNA expression and produce a
second increase in SP1 expression in later life, resulting in an increase in the transcription of
toxic AD-related proteins.
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The present study begins the process of testing our global hypothesis by examining the
expression of specific miRNA in animals that were exposed to Pb in early life. Recent reviews
have identified a small number of miRNA that consistently exhibit increased or decreased
expression

in

AD

patients

[23,

24].

We

used

the

miRTarBase

database

(http://mirtarbase.mbc.nctu.edu.tw/)[25] to select six of these miRNA that target the mRNA for
AβPP, MAPT, DNMT1,3a or 3b, SP1 and/or MECP2 and quantified their expression in animals
that were exposed to Pb to determine whether 1) their expression is altered by Pb exposure and
2) changes in miRNA levels are consistent with their potential role in the delayed overexpression
of neurotoxic AD-related proteins.
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Materials and methods
Animal exposure
All protocols were conducted in accordance with approval granted by the Institutional
Animal Care and Use Committee at the University of Rhode Island (URI). Timed pregnant
C57BL/6J strain mice were purchased from Jackson Laboratories (ME, USA) and housed at the
Animal Care Facility at URI.

Male pups from different dams were pooled and allocated

randomly to control and Pb-exposed (PbE) groups. The mothers (N = 9) of the animals in the
control group consumed tap water, whereas the mothers (N = 9) of animals in the PbE group
drank tap water containing 0.2% Pb acetate from Postnatal Day 1 (PND 1, first 24 hours after
birth) to PND 20. Three mice from the control group and three mice from the PbE group were
euthanized and their brains harvested at PND 20, 180, or 700 and their hippocampi were stored
at -80⁰C until use (total 9 control and 9 PbE animals). Tissue from these animals was used for
the present study as well as our previous investigations that determined the effect of early-life Pb
exposure on the expression of AβPP mRNA, AβPP, Aβ, Mapt mRNA and MAPT [12, 26].
Total RNA isolation and miRNA real-time polymerase chain reaction
Total RNA was extracted from control and PbE brain tissue according to the TRIzol
method (Invitrogen, CA) as per manufacturer protocol. The quality of extracted RNA was
verified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, NY).
Complementary DNA (cDNA) of miRNA was synthesized from 1 µg of total RNA using the
NCode™ VILO™ miRNA cDNA Synthesis Kit (Invitrogen, CA) as per manufacturer protocol.
The qPCR analyses of synthesized cDNA were performed using SYBR Green qRT-PCR assays
(20 µl reactions in replicates, using AβAppropriate amount of cDNA template, 10 µl SYBR
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Green master mix, 500 nM final concentration of forward and reverse primers, and deionized
water) with amplification performed in the ViiA 7 Real-Time PCR system (Applied Biosystem,
CA). The expression was reported relative to sno202 miRNA with the 2-ΔCt method.
Statistical analysis
Traditionally, real-time quantitative RT-PCR (qPCR) cycles-to-threshold (CT) values are
converted to normalized “fold” differences between groups before being subjected to statistical
analysis. A difficulty with this method is that CT values are generally Gaussian, whereas fold
differences imply proportional effects and variances that change with means. We employed a
general linear model (GLM) analytic technique [27, 28] that allowed us to test an array of linear
hypotheses accompanying our multi-factored design, including higher-order interactions. All
analyses were carried out with SAS version 9.4 (The SAS Institute, Cary, NC). Proc glimmix
was used to construct general linear models of CT values directly, which mirrored the
experimental design. The GLMs accounted for the repeated measures within mouse (multiple
miRNAs) using correlated residual errors. This was necessary as the corollary of the withinanimal subtraction of the housekeeping gene CT for normalization. A compound symmetry
variance-covariance structure was used to fit the model initially. This assumes homogenous
variances of miRNA and a common covariance between pairs of miRNA within animal.
Classical sandwich estimation was used to automatically adjust for differences in miRNA
variance and changes in covariance between pairs of miRNA. The models were 3-way factorial
models, with main effects for miRNA, treatment, and age, along with all 2-way and 3-way
interactions included in the main model. Individual a priori specified hypothesis tests were
carried out within the model as complex orthogonal comparisons, comparing groups while
normalizing to the housekeeping gene (difference of the difference = ΔΔCT). Family-wise alpha
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was maintained at 0.05 using the Holm test, though unadjusted p-values were also presented in
some instances. The (geometric) mean and 95%CI of normalized concentrations of target
miRNA (2-ΔCT) were used to illustrate how different conditions varied across time.
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Results
The expression of miR-106b (targets AβPP mRNA), miR-34c (MAPT mRNA), miR-124
(SP1 mRNA), miR-29b (DNMT3a,b; Dnmt3a,b and SP1 mRNA), miR-148a (DNMT1 and
Dnmt1 mRNA) and miR-132 (MECP2 and Mecp2 mRNA) was measured using qPCR at PND
20, 180 and 700 in animals that were exposed to Pb (and their controls) from PND 1-20 via
mothers’ milk.
miR-106b
Figure 1A illustrates the expression of miR-106b, a miRNA that has been shown to target
the mRNA for the human AβPP gene [29]. The data demonstrate that the animals responded to
Pb exposure with an increase in the production of miR-106b, but this increase was not
maintained throughout the lifespan. We found that the animals exposed to Pb had a 1.5-fold
increase in the expression of miR-106b, relative to control, at PND20 (95% confidence interval
1.1-2.1, p=0.02, adjusted p=0.28). The expression of miR-106b decreased substantially in the
Pb-exposed animals between PND20-180 and was 1.7-fold lower than levels seen in agematched control animals at PND700 (95% CL 2.2-1.1, p=0.0078, adjusted p=0.11). There was
no significant change over time in the expression of miR-106b in the animals that were not
exposed to Pb.
miR-34c
The expression of miR-34c, a miRNA that targets the mRNA for MAPT [30], is shown in
Figure 1B. We found that the expression of this miRNA remained relatively unchanged, across
the lifespan, in the animals that had been exposed to Pb. Interestingly, this contrasts with the
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expression of miR-34c in normal animals, which exhibited a dramatic increase in miR-34c levels
between PND20 and 180.

The difference between the two groups was most apparent at

PND180, where the expression of miR-34c in the control animals was 1.6-fold greater than that
seen in the Pb-exposed animals (95% CI 2.0-1.4, p<0.0001, adjusted p<0.0001).
miR-124
Figure 1C illustrates the expression of miR-124, a miRNA that targets the mRNA for SP1
[31]. The levels of miR-124 in the Pb-exposed animals remained relatively unchanged between
PND20 and 180 and reflected the levels seen in control animals.
dramatically, however, between PND180-700.

This profile changed

The expression of miR-124 in the animals

exposed to Pb decreased dramatically in this interval, and at PND700 the level of miR-124 in the
Pb-exposed animals was 2.0-fold less than the controls (95% CI 3.8-1.1, p=0.02, adjusted
p=0.33). There was no significant change over time in the expression of miR-124 in the animals
that were not exposed to Pb.
miR-29b
The expression of miR-29b, a miRNA that targets the mRNA for DNMT3 [32], Dnmt3
[33] and SP1 [34-37] mRNA, is illustrated in Figure 1D. The level of miR-29b in the animals
exposed to Pb was 1.6-fold greater than the level exhibited by controls on PND20 (95% CI 1.41.9, p<0.0001, adjusted p<0.0001).

Both groups exhibited a significant increase in the

expression of this miRNA between PND20 and PND180, with the increase associated with the
control group particularly striking. The expression of miR-29b did not change for either group
between PND180-700.
miR-148a
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Figure 1E depicts the expression of miR-148a, which has documented targets on DNMT1
[38] and Dnmt1 [39] mRNA. Comparisons at each of the three time points failed to identify any
significant differences in the expression of miR-148a in Pb-exposed and control animals.
miR-132
The expression of miR-132, which targets MECP2 [40] and Mecp2 [41] mRNA, is
illustrated in Figure 1F. We found that early life Pb exposure produced a dramatic increase
(relative to normal) in the expression of this miRNA at PND20. The level of miR-132 in the Pbexposed animals was 4.8-fold greater than the level associated with the control animals (95% CI
2.4-9.7, p<0.0001, adjusted p=0.0004).
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Discussion
The present study demonstrates that exposure to the heavy metal Pb in early life has a
significant impact on the expression of miRNA that target epigenetic mediators and neurotoxic
proteins. Brief developmental exposure to this toxicant produced an early postnatal increase
(relative to control) in the expression of a miRNA (miR-106b) that has been shown to bind to the
3’ untranslated region of AβPP mRNA, a miRNA (miR-29b) that targets SP1 and two miRNAs
(miR-29b and miR-132) that have the ability to inhibit translation of proteins involved in
promoter methylation. The expression of miR-106b decreased over time in the Pb-exposed
animals and was significantly less than the levels exhibited by the control animals at PND700.
The level of miR-124, which binds to SP1 mRNA, was also reduced (relative to controls) at
PND700.
How might we understand the evolution and potential impact of these changes in miRNA
expression? In previous studies, using the same animals employed in the present investigation,
we have demonstrated that developmental exposure to Pb produced a transient increase in the
binding of SP1 to DNA, together with a brief increase in the expression of AβPP and Mapt
mRNA [9-12]. This brief increase in AβPP and Mapt mRNA was followed by an extended
“latent” period during which the levels of these mRNA were indistinguishable from normal. As
the animals approach PND700, however, there was a latent overexpression of AβPP mRNA,
AβPP, Aβ, Mapt mRNA and hyperphosphorylated tau [9, 12, 13]. We propose that the Pbinduced transient increase in SP1 binding to DNA allows the transcription factor to increase
transcription of select miRNA, allowing them to participate in the normalization of AβPP, SP1
and MAPT levels that lasts for many months in rodents and many years in primates [9, 11, 14,
42-45]. Increased expression of miR-29b in the early postnatal period, for example, would
12	
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conceivably allow this miRNA to inhibit the production of SP1, while the early postnatal
increase in miR-106b would inhibit the expression of AβPP. Meanwhile, increased production
of miR-29b and miR-132 would act to inhibit the translation of the methylation-related proteins.
This decrease in the expression of the DNMTs and MECP2 would facilitate the continued
expression of miR-106b and miR-29b if their expression is sensitive to promoter methylation.
We predict that the miRNA that participate in the regulation of AD-related proteins are
subject to accumulating stochastic changes similar to those associated with miRNA that play a
role in oncogenesis [46-48]. We propose that the symptomatic period of LOAD is initiated by a
reduction in the expression of some of the miRNA targeting SP1, AβPP, and MAPT mRNA,
producing a decrease in post-transcriptional inhibition of SP1, AβPP and MAPT. This would
result in an increase in the expression of neurotoxic Aβ and tau.

Though the increased

availability of SP1 and continued hypomethylation of the miR-106b and miR-124 promoters
would seem to afford an opportunity to enhance transcription of these miRNA, we suggest that
the loss-of-function changes to these miRNA will have greater influence.
Conclusion
We have shown that exposure to the heavy metal Pb in early life has a significant impact
on the expression of miRNA that target epigenetic mediators and neurotoxic proteins. Three of
the six miRNA we studied exhibited an increase in expression in the period immediately
following the Pb exposure and we suggest that these and similar miRNA may participate in the
post-exposure normalization of gene expression that we have described previously. The
expression of two miRNA decreased over time in the Pb-exposed animals and we predict that
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these and related decreases in specific cerebral miRNA contribute to the over-expression of
neurotoxic proteins in later life.
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Table 1

Target	
  

miRBase	
  ID	
  

Primer	
  sequence	
  

miR-‐
29b	
  

MI0000143	
  

5’-‐GCTGGTTTCATATGGTGGTTTA-‐3’	
  

miR-‐
34c	
  

MI0000403	
  

5’-‐AGGCAGTGTAGTTAGCTGATTGC-‐3’	
  

miR-‐
106b	
  

MI0000407	
  

5’-‐TAAAGTGCTGACAGTGCAGAT-‐3’	
  

miR-‐
124	
  

MI0000716	
  

5’-‐CGTGTTCACAGCGGACCTTGAT-‐3’	
  

miR-‐
132	
  

MI0000158	
  

5’-‐AACCGTGGCTTTCGATTGTTAC-‐3’	
  

miR-‐
148	
  

MI0000550	
  

5’-‐AAAGTTCTGAGACACTCCGACT-‐3’	
  

sno-‐202	
  	
   	
  

Forward:	
  5’-‐GCTGTACTGACTTGATGAAG-‐3’	
  
Reverse:	
  5’-‐CATCAGATGGAAAAGGGTTC-‐3’	
  

	
  
Table	
  1.	
  miRNA	
  and	
  housekeeping	
  gene	
  primers	
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Fig. 1

Expression of miRNA relative to sno202 in control animals (dotted line) and Pbexposed animals (PbE, solid line) at PND 20, 180 and 700. Results expressed as mean
± 95% CI using the Holm post hoc test (p<0.05 considered significant compared to
control, indicated by *), n=3 with measurements in triplicates.
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